Aliath Bioventures

We’re proud to support INBRAIN Neuroelectronics as they secure $50M in Series B funding. This investment will fuel INBRAIN’s clinical trials and team growth as they advance their groundbreaking graphene-based brain-computer interface (BCI) technology. At only 10 micrometers thick, INBRAIN’s implant is designed to precisely decode and modulate neural signals, opening new doors in precision neurology. Congratulations to Carolina Aguilar and the INBRAIN team on this transformative milestone! #AliathBioventures #INBRAIN#Innovation #Healthcare https://lnkd.in/eBvGGr93

We’re proud to support INBRAIN Neuroelectronics as they secure $50M in Series B funding. This investment will fuel INBRAIN’s clinical trials and team growth as they advance their groundbreaking graphene-based brain-computer interface (BCI) technology. At only 10 micrometers thick, INBRAIN’s implant is designed to precisely decode and modulate neural signals, opening new doors in precision neurology. Congratulations to Carolina Aguilar and the INBRAIN team on this transformative milestone! #AliathBioventures #INBRAIN#Innovation #Healthcare https://lnkd.in/eBvGGr93

Thank you to Catalonia.Health (CataloniaBio & HealthTech) for hosting today a great conference on medical AI, where we discussed regulatory barriers, key technological and ethical challenges to achieve greater implementation and adoption in Europe. Let’s keep working towards it!

Today Aliath's team attended the World Orphan Drug Congress joining a session on the Holistic Approach to Rare Disease Drug Development: Integrating ESG, Patient Engagement, and Commercial Strategy for Improved EU Access. A great workshop! Thanks for such a fantastic session Nicholas Brooke Sheela Upadhyaya Kieron Lewis

Exciting day at the #UglyDuck24 conference! Jose Maria Fernandez and Philippe Monteyne, partners at Aliath, are attending EIF’s flagship #venturecapital conference today! The team is excited to learn and discuss the latest industry trends and future perspectives with thought leaders. Stay tuned for insights on this event! 💡 #AliathBioventures #EIFevent #Innovation #lifesciences

We are glad to announce that our colleague Montserrat Vendrell, co-founding partner of Aliath Bioventures, participated in the BNEW - Barcelona New Economy Week #BNEW2024 and shared her insights on healthcare innovation. Montserrat joined a session moderated by Santiago de Torres, Executive President of Atrys Health, with Josep Maria Campistol, director of the Hospital Clínic de Barcelona, and Manel del Castillo Rey, director of the Hospital Sant Joan de Déu Barcelona to discuss the transformative role of new technologies in healthcare. Montserrat highlighted the critical role of investors in driving innovation, particularly in disruptive technologies such as #AI, which are revolutionising diagnostics, treatments and the sustainability of healthcare systems. She stressed the importance of analysing these disruptions to understand how the market, hospitals and patients will respond. Supporting technology in healthcare is essential as its impact is far-reaching across the system. The 5th edition of BNEW was a huge success, attracting over 12,700 professionals from 106 countries and facilitating over 10,000 networking connections across seven interconnected sectors - Digital Industry, Mobility, Sustainability, Aviation, Talent, Health and Experience - the event offered a wealth of knowledge. #Innovation #Healthcare #AI #BNEW2024 #Sustainability #Investment #Technology

Ayer, 10 de octubre, participamos en el encuentro BNEW - Barcelona New Economy Week en Barcelona, que reunió a expertos de los sectores más importantes con el objetivo de "𝗰𝗼𝗻𝗲𝗰𝘁𝗮𝗿, 𝗶𝗺𝗽𝘂𝗹𝘀𝗮𝗿 𝘆 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝗿 𝗹𝗮 𝗻𝘂𝗲𝘃𝗮 𝗲𝗰𝗼𝗻𝗼𝗺𝗶́𝗮”. Nuestro presidente, Santiago de Torres, moderó la mesa dedicada al sector sanitario, “Healthtech: accesible y sostenible”, que contó con la participación de Josep M. Campistol, director general del Hospital Clínic de Barcelona; Manel del Castillo Rey, director gerente del Hospital Sant Joan de Déu Barcelona; y Montserrat Vendrell, socia confundadora de Aliath Bioventures. Durante el debate, todos los participantes subrayaron el delicado momento que atraviesa el sistema sanitario debido al incremento de la demanda, la falta de profesionales y la escasa financiación, lo que está provocando dificultades de accesibilidad, sostenibilidad y equidad del servicio. Como posibles soluciones, plantearon la necesidad de una mayor adopción de la tecnología por parte del sistema, la incorporación de nuevos perfiles al sector, o un cambio de mentalidad por parte de los propios profesionales, entre otros. “Tenemos los instrumentos tecnológicos para cambiar pero nos falta determinación. Y la tecnología nos tiene que ayudar a hacer un cambio de paradigma” afirmó Josep M. Campistol.

SPA - Società Prodotti Antibiotici and Inbiomotion sign an exclusive distribution agreement for MAF Test® in Italy SPA - Società Prodotti Antibiotici, a leading pharmaceutical company of innovative healthcare products and diagnostic tools, and Inbiomotion, proprietors of MAF Test® for identifying high risk early-stage breast cancer patients, have signed an exclusive distribution agreement to start offering the MAF Test® in Italy. The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists identify patients potentially receptive to the prevention of recurrence and who may benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated or are being treated with bisphosphonates. Thanks to this agreement, the MAF Test® could increase the survival of 8 out of 10 of the 55,000 early-stage breast cancer patients diagnosed each year in Italy. Joël Jean-Mairet, Executive Chairperson of Inbiomotion since 2012 and Executive Chairperson of Ysios Capital commented, "We are thrilled to partner with SPA - Società Prodotti Antibiotici to bring the cutting-edge MAF Test® to Italy. This collaboration represents a significant step forward in making precision medicine accessible to more patients. At Inbiomotion, our mission has always been to transform cancer treatment by providing an innovative diagnostic tool that empower both healthcare professionals and patients to make the best possible decisions. By offering a tailored approach to cancer treatment, we can significantly improve patient outcomes, reduce the likelihood of unnecessary treatments, and ultimately enhance the quality of life for those battling breast cancer. We believe that this partnership with SPA - Società Prodotti Antibiotici will play a crucial role in achieving these goals in the Italian market." # PerspectiveFromKnowledge #UncoverTheUndiscovered #CancerDiagnostics #BreastOncology #PrecisionMedicine #PatientJourney For more information: https://lnkd.in/dnerZKxZ

📣 Our Q3 newsletter is finally out! Find below more info on the portfolio companies featured on our Q3 newsletter: INBRAIN Neuroelectronics 🧠 : https://lnkd.in/eYvtpvrV Peptomyc 🧬 : https://lnkd.in/dcrmrdA9

INBRAIN Neuroelectronics Announces World’s First Human Graphene-based Brain Computer Interface Procedure INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company pioneering graphene-based neural technologies, announced today the world’s first human procedure of its cortical interface in a patient undergoing brain tumor resection. INBRAIN’s BCI technology was able to differentiate between healthy and cancerous brain tissue with micrometer-scale precision. Read more: https://lnkd.in/dbbddWGZ #INBRAINNeuroelectronics #Graphene INBRAIN Neuroelectronics #braincomputer #braintumor #cancerous #BCItechnology